Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Overview:

Research revealing that overexpression of TNF-Like Ligand 1A (TL1A) drives key inflammatory pathways in inflammatory bowel disease (IBD) has accelerated the development of biologic therapies aimed at inhibiting this ligand. Early studies of investigational anti-TL1A agents—including tulisokibart, afimkibart, and duvakitug—demonstrate encouraging outcomes in patients with moderate-to-severe IBD, showing improvements in symptoms as well as reductions in chronic intestinal inflammation and fibrosis. This high-impact symposium is tailored to gastroenterology-focused clinicians who are navigating an increasingly dynamic IBD treatment landscape. The symposium will highlight emerging evidence and potential clinical applications of anti-TNF–Like Ligand 1A therapies, featuring expert perspectives on interpreting new data. Through case-based discussions and interactive polling, participants will gain practical, up-to-date strategies to enhance IBD management and remain at the forefront of therapeutic innovation.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Summarize the limitations of currently approved advanced targeted drugs in achieving STRIDE II goals for patients with UC or CD
• Describe the role TL1A plays in the inflammatory pathophysiology of UC & CD
• Explain the mechanism of action of TL1A inhibitors in the management of UC & CD
• Evaluate clinical trial efficacy and safety data for anti-TL1A agents in the management of patients with UC or CD

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.